Brief: Sareum Completes Dosing In Study Of Phase 1a Clinical Trial For Sdc-1801

Sareum Holdings

15/02/2024 07:43

Feb 15 (Reuters) - Sareum Holdings PLC  SAR.L :
    * UPDATE ON SDC-1801 CLINICAL TRIAL PROGRESS
    * COMPLETES DOSING IN SINGLE ASCENDING DOSE (SAD) PART AND
FOOD
EFFECT STUDY OF PHASE 1A CLINICAL TRIAL FOR SDC-1801
    * PRELIMINARY RESULTS INDICATE POTENTIAL OF SDC-1801 TO
ACHIEVE
THERAPEUTICALLY EFFECTIVE DOSE LEVELS WITH NO SERIOUS ADVERSE
EVENTS

Source text for Eikon:  ID:nRSO1834Da 
Further company coverage:  SAR.L 

 ((Reuters.Briefs@thomsonreuters.com;;))